Backed by Mayo Clinic, Nutrix's hardware monitors worker stress
Stress isn't just bad for you — it's also bad for your employer. Factoring in absenteeism, diminished productivity, turnover, medical costs, and accidents, the nonprofit American Institute of Stress estimates that workplace stress costs U.S. businesses over $300 billion annually.
One way to measure stress is by monitoring cortisol levels. Even influencers know this, with 'cortisol face' becoming a trending TikTok topic. But to approach things scientifically, the hormone needs to be measured throughout the day, because it's variation that matters the most.
'By the end of the day, we should have the lowest levels,' says Nutrix CEO Maria Hahn. Her company's newly unveiled hardware, cortiSense, which measures cortisol in saliva, recently won the CES Innovation Award 2025 in the Digital Health category.
Providing patients with a device instead of having them go to a clinic isn't just more convenient; it also allows for tracking cortisol levels right after waking up, Hahn told TechCrunch.
Developed with the support of the University of Applied Sciences Northwestern Switzerland, cortiSense integrates with Nutrix's digital health platform, gSense, which includes a digital health platform, continuous glucose monitoring, AI-powered dietary management, and telemedicine.
This also connects with Nutrix's initial focus: diabetes. While it pivoted its hardware roadmap toward cortiSense, the company's eye is still on chronic diseases. 'Cortisol is a hormone that controls many other hormones, so it plays an important role in mental health, but also metabolic health,' the Switzerland-based entrepreneur said.
This vision helped Nutrix gain support from Swiss innovation agency, Innosuisse, as well as private investment. The startup raised $4 million to date, including a previously unannounced $2.5 million seed round co-led by Polish impact fund Simpact and Japan deep tech fund OIST-Lifetime Ventures. Mayo Clinic also came on board, after meeting the team at CES 2024.
The startup is seeking to raise a large Series A round to fund its expansion, but its seed round has already kicked off the U.S. launch of cortiSense. With support from the Mayo Clinic, it is planning to open offices in Silicon Valley.
Nutrix isn't new to market expansion; its gSense platform is integrated with the public insurance system in Chile, a country where it received support from public program Start-Up Chile. In 2024, the Swiss health tech startup also launched operations in Mexico and Peru.
What's new for Nutrix, however, is the pushback over a model that targets corporations, rather than consumers. While less common in the U.S., in countries such as Chile, Mexico, and Peru, health screenings are part of an employers' obligation to strive for employee wellness, with an understanding that private health data remains private.
With the U.S. now at the top of Nutrix's cortiSense roadmap, Hahn will have to get used to clarifying 'the company will only get the aggregated data.' And while a utilitarian pitch around the economic costs of job stress may seem distasteful to some, it may also serve as a reminder to employers that mental health is, indeed, health.
Cortisol is, 'also extremely important in women's health, especially in the perimenopause and menopause, but it's also a space that was very abandoned from the research and studies point of view,' Hahn said. She now plans to use some of Nutrix's funding to conduct further investigations into these ties. 'For me as a woman, that's also very important,' she said.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
an hour ago
- Yahoo
Japan's ispace fails second lunar landing mission
Japan'sprivate moon mission was aborted on Friday after it was presumed that the unmanned Resilience spacecraft had crashed. Tokyo-based startup ispace had launched the mission in hopes of becoming the first private company outside the United States to achieve a controlled lunar landing. The Resilience spacecraft had begun its final descent, successfully firing its main engine "as planned to begin deceleration," ispace said. Mission control reported that the craft's position was "nearly vertical," but contact was then lost. ispace stated that the spacecraft had likely failed to decelerate sufficiently to reach the speed required for a soft lunar landing. "Based on the currently available data... it is currently assumed that the lander likely performed a hard landing. It is unlikely that communication with the lander will be restored, so it has been decided to conclude the mission," ispace said in a statement. As of 8:00 a.m. on June 6, 2025, mission controllers have determined that it is unlikely that communication with the lander will be restored and therefore completing Success 9 is not achievable. It has been decided to conclude the mission.'Given that there is currently no… — ispace (@ispace_inc) June 6, 2025 Before signing off, the livestream announcers said, "never quit the lunar quest." Less than two minutes before the scheduled landing, the once-celebratory gathering of 500 ispace employees, shareholders, sponsors, and government officials fell into stunned silence as contact with the spacecraft was lost. "Expectations for ispace will not waver," Japanese Prime Minister Shigeru Ishiba posted on X. ispaceによる月面着陸は、残念ながら成功には至りませんが、この挑戦が持つ価値は一時的にできるものではありません。 ispaceに対する期待が揺らぐことはありません。そのためにも、すぐに課題を検証し、次なる飛躍につなげていただきたいと願っています。 — 石破茂 (@shigeruishiba) June 6, 2025 Two years ago, another lunar missionby the company had also ended in a crash. CEO Takeshi Hakamada told reporters he took the second failed attempt "seriously" and intended to use the outcome to inform future missions. He said they had a "strong will to move on, although we have to carefully analyze what happened." Resilience carried a four-wheeled rover built by ispace's Luxembourg subsidiary, along with five external payloads valued at a total of $16 million. The planned landing site was Mare Frigoris, a plain about 900 km (560 miles) from the moon's north pole. Lunar landings remain challenging due to the moon's rugged terrain. To date, only five nations have successfully achieved soft lunar landings: Russia, US, China, India and Japan. Private companies have recently entered the race to the moon, and ispace would have been the third such company to achieve it. The mission wanted to collect two lunar soil samples and sell them to NASA for $5,000 (€4373). In January, Resilience shared a SpaceX rocket launch with Firefly's Blue Ghost lander, which touched down successfully in March. A moon landing attempt by US-based company Intuitive Machines failed in March this year. Edited by: Louis Oelofse
Yahoo
an hour ago
- Yahoo
New FDA-approved Alzheimer's blood test coming to Mayo Clinic
The Brief The FDA has approved the marketing of a new blood test by Fujirebio. The biomarker test measures the ratio of tau and amyloid proteins in the blood of a person with symptoms of cognitive decline to confirm the presence of Alzheimer's disease. Mayo Clinic will be one of 37 Alzheimer's clinics across the country to receive the new blood testing equipment starting at the end of June. MINNEAPOLIS (FOX 9) - The U.S. Food and Drug Administration has approved the marketing of a new tool to that can test a person's blood to diagnose Alzheimer's disease. The blood test is a groundbreaking development to confirm the disease in patients who are already experiencing cognitive decline. What we know The diagnostic tool, called Lumipulse, is manufactured by the world-wide medical research and development firm Fujirebio. The procedure, called the G pTau 217/β-Amyloid 1-42 Plasma Ratio in-vitro diagnostic (IVD) test, measures the presence of the amyloid and tau proteins in the brain that build the plaques leading to Alzheimer's disease. Fujirebio will now start distributing the diagnostic tests by the end of June to 37 Alzheimer's clinics across the United States including Mayo Clinic in Rochester, Minnesota. "I was very excited to get the news that there was an FDA approved test," said Alicia Algeciras-Schimnich, Ph.D. of Mayo Clinic who's been offering a version of the blood test for the past year in their laboratory. "It's just increasing the access to patients, and now many more laboratories will be able to offer this test." Dr. Algeciras-Schimnich says Mayo hopes will have the capacity to offer 1,000 to 5,000 blood tests a month with this new diagnostic protocol. What patients say Tim Sandry admits he's never had the best memory, but when he approached turning 67, he and his wife Ellen started noticing changes. "I wanted to find out what's going on here," recalled Sandry when he and his wife decided to see a neurologist. The doctor put him through a series of cognitive tests and determined he had what's called mild cognitive impairment which is a noticeable slowing of memory function. It wasn't long after his cognitive tests that a new diagnostic spinal tap was available to detect the presence of Alzheimer's disease. But it was invasive and painful. "In the morning they took the spinal fluid, and then I had to stay very still for the rest of the day. And then they sent me home, and I had an awful headache for the next three days," said Sandry of the hospital procedure. This new test would have saved him the pain and provided reliable results. "Oh, so much difference," said Sandry about the chance to have had a diagnostic blood test. "I mean, this blood test is going to shake things up dramatically I believe." Why you should care The faster a person experiencing cognitive decline can get a positive diagnosis for Alzheimer's the faster they can start taking one of two recently FDA approved drugs to slow the progression of the disease. Those drugs are Leqembi and Kisunla. "It makes it much quicker for those people to start treatment and to start looking at what options there are, whether it's clinical trials or medication," said Jenna Fink of the Alzheimer's Association Minnesota-North Dakota chapter. Sandry has been on a regimen of Leqembi since his own diagnosis and he believes it has dramatically slowed the disease in his own brain. "The sooner you get diagnosed, the quicker you can get on those drugs and the less damage this will do to your brain And the longer you will be able to function, cognitively," he said. Dig deeper The new blood test not only speeds up the diagnosis process, it also offers more accuracy. "The clinical diagnosis of Alzheimer disease is only about 70-75% accurate," said Mayo's Alicia Algeciras-Schimnich of the standard practice of cognitive testing and PET scans of the brain. Adding the blood biomarker test increases the accuracy of an Alzheimer's diagnosis to 90-95%. "So really, it is a significant improvement in the diagnosis for patients, which now can have an earlier answer for their symptoms," said Algeciras-Schmnich.' By the numbers As many as 101,900 Minnesotan over the age of 65 are living with Alzheimer's according to the 2025 facts and figures report from the Alzheimer's Association. That adds up to 10.7% of Minnesota adults over 65. Alzheimer's affects more than just the patients. For every patient, there are caregivers, many of them family members. When those numbers are added up, the Alzheimer's Association estimates there are 166,000 caregivers in Minnesota. Across the nation, 7.2 million Americans are living with the Alzheimer's, and 74% are over the age of 75.


CNN
2 hours ago
- CNN
Morten Harket, lead singer of a-ha, has Parkinson's disease
Morten Harket has revealed he has Parkinson's disease. The singer of a-ha, the band behind the 1985 hit and innovatively animated music video 'Take On Me,' shared the news during an interview with the group's biographer. 'I've got no problem accepting the diagnosis,' Harket said. 'With time, I've taken to heart my 94-year-old father's attitude to the way the organism gradually surrenders: 'I use whatever works'.' Harket, 65, explained why he wanted to share his diagnosis publicly. 'Acknowledging the diagnosis wasn't a problem for me; it's my need for peace and quiet to work that has been stopping me. I'm trying the best I can to prevent my entire system from going into decline,' he said. 'It's a difficult balancing act between taking the medication and managing its side effects. There's so much to weigh up when you're emulating the masterful way the body handles every complex movement, or social matters and invitations, or day-to-day life in general.' According to Mayo Clinic, 'Parkinson's disease is a movement disorder of the nervous system that worsens over time.' Harket had 'advanced brain surgery' at the Mayo Clinic, which along with medication, 'have softened the impact of his symptoms,' the a-ha biographer, Jan Omdahl, wrote. 'In June 2024, Morten underwent a neurosurgical procedure in which electrodes were implanted deep inside the left side of his brain. These are connected to a small pacemaker-like device placed under the skin of the upper chest that sends electrical impulses through the electrodes into the brain,' Omdahl wrote. 'The method is called deep brain stimulation (DBS) and is among the most advanced treatments in neurology. The procedure had the desired effect: with the right electrical impulses now reaching Morten's brain, many of his physical symptoms practically vanished. In December 2024 he underwent a similar procedure on the right side of his brain, which was also successful.' Harket's voice, however, has been affected, he said. 'The problems with my voice are one of many grounds for uncertainty about my creative future,' Harket said.